DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 204 filers reported holding DICERNA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.78 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $15,058,000 | +66.4% | 588,910 | +17.1% | 1.41% | +94.2% |
| Q3 2020 | $9,049,000 | -75.8% | 503,012 | -65.9% | 0.72% | -79.1% |
| Q2 2020 | $37,429,000 | +21.3% | 1,473,568 | -12.3% | 3.47% | -2.9% |
| Q1 2020 | $30,850,000 | -29.3% | 1,679,344 | -15.3% | 3.57% | +13.4% |
| Q4 2019 | $43,655,000 | +14.4% | 1,981,633 | -25.5% | 3.15% | -0.2% |
| Q3 2019 | $38,172,000 | -41.9% | 2,658,196 | -36.3% | 3.15% | -38.8% |
| Q2 2019 | $65,694,000 | -6.1% | 4,171,065 | -12.6% | 5.16% | -6.8% |
| Q1 2019 | $69,935,000 | +37.0% | 4,773,718 | 0.0% | 5.54% | +30.1% |
| Q4 2018 | $51,031,000 | -39.5% | 4,773,718 | -13.7% | 4.25% | -12.9% |
| Q3 2018 | $84,388,000 | +113.6% | 5,530,028 | +71.4% | 4.88% | +128.1% |
| Q2 2018 | $39,513,000 | +236.9% | 3,225,527 | +162.9% | 2.14% | +201.0% |
| Q1 2018 | $11,728,000 | +43.4% | 1,226,820 | +35.4% | 0.71% | +31.7% |
| Q4 2017 | $8,181,000 | – | 905,998 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,355,392 | $29,859,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $67,858,000 | 4.26% |
| DAFNA Capital Management LLC | 587,756 | $12,948,000 | 3.85% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 227,388 | $5,009,000 | 2.91% |
| RTW INVESTMENTS, LP | 7,253,857 | $159,802,000 | 2.68% |
| Parkman Healthcare Partners LLC | 331,513 | $7,303,000 | 1.87% |
| Evolutionary Tree Capital Management, LLC | 60,864 | $1,341,000 | 1.02% |
| Eagle Health Investments LP | 69,000 | $1,520,000 | 0.97% |
| Woodline Partners LP | 1,358,796 | $29,934,000 | 0.79% |
| Affinity Asset Advisors, LLC | 40,000 | $881,000 | 0.47% |